共 50 条
- [1] BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation studyANNALS OF ONCOLOGY, 2018, 29Hu, X.论文数: 0 引用数: 0 h-index: 0机构: Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp, Beijing, Peoples R China Peking Union Med Coll, Beijing, Peoples R China Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp, Beijing, Peoples R ChinaZheng, X.论文数: 0 引用数: 0 h-index: 0机构: Peking Union Med Coll Hosp, Clin Pharmacol Res Ctr, Beijing, Peoples R China Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp, Beijing, Peoples R ChinaMo, H.论文数: 0 引用数: 0 h-index: 0机构: Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp, Beijing, Peoples R China Peking Union Med Coll, Beijing, Peoples R China Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp, Beijing, Peoples R ChinaCui, X.论文数: 0 引用数: 0 h-index: 0机构: Peking Union Med Coll Hosp, Clin Pharmacol Res Ctr, Beijing, Peoples R China Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp, Beijing, Peoples R ChinaDing, L.论文数: 0 引用数: 0 h-index: 0机构: Bettapharma Pharmaceut Co Ltd, Hangzhou, Zhejiang, Peoples R China Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp, Beijing, Peoples R ChinaTan, F.论文数: 0 引用数: 0 h-index: 0机构: Bettapharma Pharmaceut Co Ltd, R&D Ctr, Beijing, Peoples R China Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp, Beijing, Peoples R ChinaHu, P.论文数: 0 引用数: 0 h-index: 0机构: Peking Union Med Coll Hosp, Clin Pharmacol Res Ctr, Beijing, Peoples R China Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp, Beijing, Peoples R ChinaShi, Y.论文数: 0 引用数: 0 h-index: 0机构: Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp, Beijing, Peoples R China Peking Union Med Coll, Beijing, Peoples R China Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp, Beijing, Peoples R China
- [2] BPI-9016M, a Novel c-Met Inhibitor, in Pretreated Advanced Solid Tumor: Results from a First-In-Human, Phase 1, Dose-Escalation StudyJOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S474 - S474Hu, X.论文数: 0 引用数: 0 h-index: 0机构: Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China Peking Union Med Coll, Beijing, Peoples R China Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R ChinaZheng, X.论文数: 0 引用数: 0 h-index: 0机构: Beijing Union Med Coll Hosp, Beijing, Peoples R China Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R ChinaMo, H.论文数: 0 引用数: 0 h-index: 0机构: Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China Peking Union Med Coll, Beijing, Peoples R China Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R ChinaCui, X.论文数: 0 引用数: 0 h-index: 0机构: Beijing Union Med Coll Hosp, Beijing, Peoples R China Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R ChinaDing, L.论文数: 0 引用数: 0 h-index: 0机构: Bettapharma Pharmaceut Co Ltd, Hangzhou, Zhejiang, Peoples R China Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R ChinaTan, F.论文数: 0 引用数: 0 h-index: 0机构: Bettapharma Pharmaceut Co Ltd, Hangzhou, Zhejiang, Peoples R China Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R ChinaHu, P.论文数: 0 引用数: 0 h-index: 0机构: Beijing Union Med Coll Hosp, Beijing, Peoples R China Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R ChinaShi, Y.论文数: 0 引用数: 0 h-index: 0机构: Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China Peking Union Med Coll, Beijing, Peoples R China Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
- [3] First-in-human phase I dose-escalation study of the oral selective C-met inhibitor EMD 1204831 in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Amin, Hesham M.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USAFalchook, Gerald Steven论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USAFu, Siqing论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USAHong, David S.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USATsimberidou, Apostolia Maria论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USANaing, Aung论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USAWheler, Jennifer J.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USAPiha-Paul, Sarina Anne论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USAJanku, Filip论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USAKlevesath, Manfred B.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USAJego, Virginie论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USAJohne, Andreas论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USAKurzrock, Razelle论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
- [4] First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancerJournal of Hematology & Oncology, 13Xingsheng Hu论文数: 0 引用数: 0 h-index: 0机构: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical OncologyXin Zheng论文数: 0 引用数: 0 h-index: 0机构: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical OncologySheng Yang论文数: 0 引用数: 0 h-index: 0机构: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical OncologyLin Wang论文数: 0 引用数: 0 h-index: 0机构: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical OncologyXuezhi Hao论文数: 0 引用数: 0 h-index: 0机构: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical OncologyXinge Cui论文数: 0 引用数: 0 h-index: 0机构: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical OncologyLieming Ding论文数: 0 引用数: 0 h-index: 0机构: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical OncologyLi Mao论文数: 0 引用数: 0 h-index: 0机构: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical OncologyPei Hu论文数: 0 引用数: 0 h-index: 0机构: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical OncologyYuankai Shi论文数: 0 引用数: 0 h-index: 0机构: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical Oncology
- [5] First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancerJOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)Hu, Xingsheng论文数: 0 引用数: 0 h-index: 0机构: Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol,Natl Canc Ctr,Canc Hosp, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol,Natl Canc Ctr,Canc Hosp, 17 Panjiayuan Nanli, Beijing 100021, Peoples R ChinaZheng, Xin论文数: 0 引用数: 0 h-index: 0机构: Peking Union Med Coll Hosp, Clin Pharmacol Res Ctr, 41 Damucang Hutong, Beijing 100032, Peoples R China Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol,Natl Canc Ctr,Canc Hosp, 17 Panjiayuan Nanli, Beijing 100021, Peoples R ChinaYang, Sheng论文数: 0 引用数: 0 h-index: 0机构: Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol,Natl Canc Ctr,Canc Hosp, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol,Natl Canc Ctr,Canc Hosp, 17 Panjiayuan Nanli, Beijing 100021, Peoples R ChinaWang, Lin论文数: 0 引用数: 0 h-index: 0机构: Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol,Natl Canc Ctr,Canc Hosp, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol,Natl Canc Ctr,Canc Hosp, 17 Panjiayuan Nanli, Beijing 100021, Peoples R ChinaHao, Xuezhi论文数: 0 引用数: 0 h-index: 0机构: Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol,Natl Canc Ctr,Canc Hosp, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol,Natl Canc Ctr,Canc Hosp, 17 Panjiayuan Nanli, Beijing 100021, Peoples R ChinaCui, Xinge论文数: 0 引用数: 0 h-index: 0机构: Peking Union Med Coll Hosp, Clin Pharmacol Res Ctr, 41 Damucang Hutong, Beijing 100032, Peoples R China Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol,Natl Canc Ctr,Canc Hosp, 17 Panjiayuan Nanli, Beijing 100021, Peoples R ChinaDing, Lieming论文数: 0 引用数: 0 h-index: 0机构: Betta Pharmaceut Co Ltd, Hangzhou, Zhejiang, Peoples R China Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol,Natl Canc Ctr,Canc Hosp, 17 Panjiayuan Nanli, Beijing 100021, Peoples R ChinaMao, Li论文数: 0 引用数: 0 h-index: 0机构: Betta Pharmaceut Co Ltd, Hangzhou, Zhejiang, Peoples R China Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol,Natl Canc Ctr,Canc Hosp, 17 Panjiayuan Nanli, Beijing 100021, Peoples R ChinaHu, Pei论文数: 0 引用数: 0 h-index: 0机构: Peking Union Med Coll Hosp, Clin Pharmacol Res Ctr, 41 Damucang Hutong, Beijing 100032, Peoples R China Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol,Natl Canc Ctr,Canc Hosp, 17 Panjiayuan Nanli, Beijing 100021, Peoples R ChinaShi, Yuankai论文数: 0 引用数: 0 h-index: 0机构: Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol,Natl Canc Ctr,Canc Hosp, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol,Natl Canc Ctr,Canc Hosp, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China
- [6] First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumorsEUROPEAN JOURNAL OF CANCER, 2015, 51 : S54 - S54Azaro, A.论文数: 0 引用数: 0 h-index: 0机构: Vall dHebron Inst Oncol, Med Oncol, Barcelona, Spain Vall dHebron Inst Oncol, Med Oncol, Barcelona, SpainRodon, J.论文数: 0 引用数: 0 h-index: 0机构: Vall dHebron Inst Oncol, Med Oncol, Barcelona, Spain Vall dHebron Inst Oncol, Med Oncol, Barcelona, SpainHerranz, M.论文数: 0 引用数: 0 h-index: 0机构: Vall dHebron Inst Oncol, Med Oncol, Barcelona, Spain Vall dHebron Inst Oncol, Med Oncol, Barcelona, SpainNuciforo, P.论文数: 0 引用数: 0 h-index: 0机构: Vall dHebron Inst Oncol, Mol Oncol Lab, Barcelona, Spain Vall dHebron Inst Oncol, Med Oncol, Barcelona, SpainPrudkin, L.论文数: 0 引用数: 0 h-index: 0机构: Vall dHebron Inst Oncol, Mol Oncol Lab, Barcelona, Spain Vall dHebron Inst Oncol, Med Oncol, Barcelona, SpainLopez-Busto, N.论文数: 0 引用数: 0 h-index: 0机构: Innovat Therapeut Pole, Inst Rech Int Servier, Suresnes, France Vall dHebron Inst Oncol, Med Oncol, Barcelona, SpainBalandraud, S.论文数: 0 引用数: 0 h-index: 0机构: Innovat Therapeut Pole, Inst Rech Int Servier, Suresnes, France Vall dHebron Inst Oncol, Med Oncol, Barcelona, SpainCattan, V.论文数: 0 引用数: 0 h-index: 0机构: Innovat Therapeut Pole, Inst Rech Int Servier, Suresnes, France Vall dHebron Inst Oncol, Med Oncol, Barcelona, SpainJacquet-Bescond, A.论文数: 0 引用数: 0 h-index: 0机构: Innovat Therapeut Pole, Inst Rech Int Servier, Suresnes, France Vall dHebron Inst Oncol, Med Oncol, Barcelona, SpainMarfai, L.论文数: 0 引用数: 0 h-index: 0机构: Innovat Therapeut Pole, Inst Rech Int Servier, Suresnes, France Vall dHebron Inst Oncol, Med Oncol, Barcelona, SpainPauly, J.论文数: 0 引用数: 0 h-index: 0机构: Innovat Therapeut Pole, Inst Rech Int Servier, Suresnes, France Vall dHebron Inst Oncol, Med Oncol, Barcelona, SpainPostel-Vinay, S.论文数: 0 引用数: 0 h-index: 0机构: DITEP, Villejuif, France Vall dHebron Inst Oncol, Med Oncol, Barcelona, SpainHollebecque, A.论文数: 0 引用数: 0 h-index: 0机构: DITEP, Villejuif, France Vall dHebron Inst Oncol, Med Oncol, Barcelona, SpainSoria, J. C.论文数: 0 引用数: 0 h-index: 0机构: DITEP, Villejuif, France Vall dHebron Inst Oncol, Med Oncol, Barcelona, Spain
- [7] First-in-human Phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors.MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)Hollebecque, Antoine论文数: 0 引用数: 0 h-index: 0机构: Inst Cancerol Gustave Roussy, Villejuif, France Inst Cancerol Gustave Roussy, Villejuif, FranceSoria, Jean-Charles论文数: 0 引用数: 0 h-index: 0机构: Inst Cancerol Gustave Roussy, Villejuif, France Inst Cancerol Gustave Roussy, Villejuif, FranceBahleda, Ratislav论文数: 0 引用数: 0 h-index: 0机构: Inst Cancerol Gustave Roussy, Villejuif, France Inst Cancerol Gustave Roussy, Villejuif, FranceLopez-Busto, Natividad论文数: 0 引用数: 0 h-index: 0机构: Inst Rech Int Servier, Suresnes, France Inst Cancerol Gustave Roussy, Villejuif, FranceJacquet-Bescond, Anne论文数: 0 引用数: 0 h-index: 0机构: Inst Rech Int Servier, Suresnes, France Inst Cancerol Gustave Roussy, Villejuif, FranceBurbridge, Mike F.论文数: 0 引用数: 0 h-index: 0机构: Inst Rech Servier, Croissy Sur Seine, France Inst Cancerol Gustave Roussy, Villejuif, FranceValerie, Cattan论文数: 0 引用数: 0 h-index: 0机构: Inst Rech Int Servier, Suresnes, France Inst Cancerol Gustave Roussy, Villejuif, FrancePauly, Jeanne论文数: 0 引用数: 0 h-index: 0机构: Inst Rech Int Servier, Suresnes, France Inst Cancerol Gustave Roussy, Villejuif, FranceHerranz, Maria论文数: 0 引用数: 0 h-index: 0机构: Vall dHebron Univ Hosp, Barcelona, Spain Inst Cancerol Gustave Roussy, Villejuif, FranceAzaro, Analia论文数: 0 引用数: 0 h-index: 0机构: Vall dHebron Univ Hosp, Barcelona, Spain Inst Cancerol Gustave Roussy, Villejuif, FranceDepil, Stephane论文数: 0 引用数: 0 h-index: 0机构: Inst Rech Int Servier, Suresnes, France Inst Cancerol Gustave Roussy, Villejuif, FranceRodon, Jordi论文数: 0 引用数: 0 h-index: 0机构: Vall dHebron Univ Hosp, Barcelona, Spain Inst Cancerol Gustave Roussy, Villejuif, France
- [8] Phase I Dose-escalation Study of the Oral Selective C-Met Inhibitor EMD 1204831 in Patients With Advanced Solid TumoursEUROPEAN JOURNAL OF CANCER, 2011, 47 : S158 - S158Falchook, G. S.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USAFu, S.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USAAmin, H. M.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USATsimberdiou, A. M.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USAHong, D. S.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USANaing, A.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USAKlevesath, M. B.论文数: 0 引用数: 0 h-index: 0机构: Merck KGaA, Darmstadt, Germany Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USAMattiacci, M. R.论文数: 0 引用数: 0 h-index: 0机构: Merck Serono Int SA, Geneva, Switzerland Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USAJohne, A.论文数: 0 引用数: 0 h-index: 0机构: Merck KGaA, Darmstadt, Germany Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USAKurzrock, R.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA
- [9] A Phase I Dose-escalation Study of EMD 1214063, an Oral Selective C-Met Inhibitor, in Patients With Advanced Solid TumoursEUROPEAN JOURNAL OF CANCER, 2011, 47 : S158 - S158Falchook, G. S.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USAFu, S.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USAAmin, H. M.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USAPiha-Paul, S. A.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USAHong, D. S.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USANaing, A.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USAKlevesath, M. B.论文数: 0 引用数: 0 h-index: 0机构: Merck KGaA, Darmstadt, Germany Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USAMattiacci, M. R.论文数: 0 引用数: 0 h-index: 0机构: Merck Serono Int SA, Geneva, Switzerland Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USADi Cara, A.论文数: 0 引用数: 0 h-index: 0机构: Merck Serono Int SA, Geneva, Switzerland Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USAKurzrock, R.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA
- [10] PHASE I DOSE-ESCALATION STUDY OF ORAL SELECTIVE C-MET INHIBITOR EMD 1214063 IN PATIENTS WITH ADVANCED SOLID TUMORSANNALS OF ONCOLOGY, 2012, 23 : 154 - 154Falchook, G. S.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USAHong, D. S.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USAAmin, H. M.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USAFu, S.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USAPiha-Paul, S. A.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USAKlevesath, M. B.论文数: 0 引用数: 0 h-index: 0机构: Merck KGaA, Global Early Dev Unit Oncol, Darmstadt, Germany Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USAJego, V.论文数: 0 引用数: 0 h-index: 0机构: Merck Serono, Biostat Geneva, Geneva, Switzerland Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USAJohne, A.论文数: 0 引用数: 0 h-index: 0机构: Merck KGaA, Clin Pharmacol, Darmstadt, Germany Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USAStinchi, S.论文数: 0 引用数: 0 h-index: 0机构: Merck Serono RBM, Ist Ric Biomed, Colleretto Giacosa, Italy Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USAKurzrock, R.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA